Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 26

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 26
---
 prospectus supplement to provide information about any such methods of distribution
as required by Rule 424(b) under the Securities Act.

Each time we wish to issue and sell shares of
common stock under the Sales Agreement, we will notify Jones of the number of shares to be issued, the dates on which such sales are anticipated
to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made.
Once we have so instructed Jones, unless Jones declines to accept the terms of such notice, Jones has agreed to use its commercially reasonable
efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations
of Jones under the Sales Agreement to sell shares of our common stock are subject to a number of conditions that we must meet. The settlement
of sales of shares between us and Jones is generally anticipated to occur on the first trading day following the date on which the sale
was made. Sales of shares of our common stock as contemplated in this prospectus supplement will be settled through the facilities of
The Depository Trust Company or by such other means as we and Jones may agree upon. There is no arrangement for funds to be received in
an escrow, trust or similar arrangement.

We will pay Jones a commission of up to 3.0% of
the aggregate gross proceeds we receive from each sale of shares of our common stock. Because there is no minimum offering amount required
as a condition of this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable
at this time. In addition, we have agreed to reimburse Jones for certain fees and disbursements of its counsel. We estimate that the total
expenses for the offering, excluding any commissions or expense reimbursement payable to Jones under the terms of the Sales Agreement,
will be approximately $450,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from
the sale of such shares.

Jones will provide written confirmation to us
before the open on the NYSE American on the day following each day on which shares of our common stock are sold under the Sales Agreement.
Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us.

In connection with the sale of shares of our common
stock on our behalf, Jones will be deemed to be an “underwriter” within the